FDA Approves Alhemo for Patients with Hemophilia
Routine prophylaxis to prevent or reduce bleedingFor Patients with Hemophilia A or B with Inhibitors
The FDA has approved Alhemo (concizumab-mtci) for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with:
- Hemophilia A with factor VIII inhibitors, or
- Hemophilia B with factor IX inhibitors.
What It Is
- Alhemo is a subcutaneous (under the skin) injection, taken daily.
- It’s designed for patients who have developed inhibitors — antibodies that block standard clotting factor treatments.
Effectiveness
- In a global phase 3 trial, Alhemo reduced annual bleeding rates by 86% compared to no prophylaxis.
- Participants included 91 adults and 42 adolescents with hemophilia A or B, with inhibitors.
Safety Info
- Most common side effects: Injection site reactions and hives.
- May cause hypersensitivity (rash, itching, abdominal pain) and increased risk of blood clots.
- Not recommended for patients with serious allergies to the drug or its ingredients.
Special FDA Designations
- Priority Review
- Orphan Drug status (for rare conditions)
Alhemo offers a new preventative option for a high-risk hemophilia population where standard clotting therapies may fail.
Editor’s Note: This is another in our series of potentially game-changing novel pharmaceuticals that FDA approved in 2024 and 2025. This approval report does not in any way recommend or promote this product. For more information contact your oncologist or the manufacturer. Report any adverse effects experienced with this product to FDA’s Medwatch System.
FDA Warns of Risks with OTC Pain Relief Products
The U.S. Food and Drug Administration (FDA) has issued a stern warning to consumers regarding the use of certain over-the-counter analgesic (pain relief) products intended for topical use before, during, or after various cosmetic procedures like microdermabrasion,...
FDA Approves Treatment for Platinum-Resistant Ovarian Cancer
In a significant development for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, on March 22, 2024 the Food and Drug Administration (FDA) granted approval for mirvetuximab soravtansine-gynx, marketed as Elahere by...
Urgent Recall Alert for Methocarbamol Injection by Eugia US LLC
Attention Consumers, Healthcare Providers, and Distributors: Eugia US LLC, formerly known as AuroMedics Pharma LLC, announced a voluntary recall on March 28, 2024 of lot number 3MC23011 of Methocarbamol Injection, USP 1000 mg/10 mL (100mg/mL) 10mL Single Dose Vial....